Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-5806 (Presatovir) in HCT Recipients with RSV Lower Respiratory Tract Infection
2014-002475-29Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Presatovir arm with Placebo arm (2 arms). Primary endpoint: Time-weighted average change in nasal RSV viral load from baseline to Day 9. Started Dec 2014; status: completed.
02
Drugs
presatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2014-002475-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002475-29.